Agreement in the identification of microcrystals (kappa index) compared with reference with and without DMSO for both observers (disagreement shown in bold and underlined)
Reference | DMSO+ observer 1 | DMSO+ observer 2 | DMSO− observer 1 | Observer 2 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Negative | MSU | CPP | Negative | MSU | CPP | Negative | MSU | CPP | Negative | MSU | CPP | |
Negative | 12 | 0 | 0 | 2 | 1 | 1 | 11 | 0 | 1 | 0 | 0 | 0 |
MSU | 0 | 8 | 0 | 0 | 8 | 0 | 1 | 7 | 0 | 5 | 1 | 0 |
CPP | 0 | 0 | 10 | 0 | 0 | 9 | 4 | 0 | 6 | 2 | 1 | 2 |
Agreement kappa: 1.00 for reference vs. DMSO+ observer 1; kappa: 0.845 for reference vs. DMSO+ observer 2; kappa: 0.691 for reference vs. DMSO− observer 2; kappa: 0.111 for reference vs. DMSO− observer 2
FPR, ELB, FL, NS, TU, and JJMM: Conceptualization, Writing—review & editing. FPR and ELB: Data curation, Writing—original draft. FPR, ELB, FL, NS, TU, and JJMM read and approved the submitted version.
The authors declare that they have no conflicts of interest.
The study was included within a prospective inception gout cohort study approved by Cruces University Hospital Ethics and Clinical Investigation Committee (CEIC Cruces).
Written informed consent was obtained and signed by patients and investigators to use exceeds of biological samples, and approved by the CEIC Cruces.
Not applicable.
Data can be obtained by contacting Fernando Pérez-Ruiz (fernando.perezruiz@osakidetza.eus).
FPR was funded by a grant from Asociación de Reumatólogos de Cruces [04/2022]. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2023.